Pulse Biosciences, Inc. (Nasdaq: PLSE) , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late ...

MIAMI, February 04, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA ...

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation ...

Current Co-Chairman of the Board will now also serve as Chief Executive Officer Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its ...

This page features the latest news about the Pulse Biosciences stock. Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium Nanosecond PFA 360 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(RTTNews) - Pulse Biosciences, Inc. (PLSE), a novel bioelectric medicine company, Tuesday announced the appointment of Jon Skinner as Chief Financial Officer, with effect from February 3.

Pulse Biosciences (PLSE) announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3. “I am excited to announce Jon as our next CFO, further building upon our ...